Thomas Hogan Sells 25,299 Shares of Cellebrite DI (NASDAQ:CLBT) Stock

Key Points

• Insider sale: Thomas Hogan sold 25,299 Cellebrite DI shares for approximately $285,626 at an average price of $11.29, reducing his direct stake by 3.2% to 765,249 shares.
• Stock performance: CLBT shares rose 5.8% to $12.29, though they remain below their 50-day and 200-day moving averages. The company has a $3.07 billion market capitalization and a price-to-earnings ratio of 55.87.
• Analyst outlook: Analysts have cut their price targets, but five maintain Buy ratings versus one Sell rating. The stock has a “Moderate Buy” consensus rating and an average target price of $16.70.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) insider Thomas Hogan sold 25,299 shares of the firm's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $11.29, for a total value of $285,625.71. Following the transaction, the insider directly owned 765,249 shares of the company's stock, valued at $8,639,661.21. The trade was a 3.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Cellebrite DI Trading Up 5.8%

Shares of NASDAQ CLBT traded up $0.67 during trading on Thursday, reaching $12.29. The company had a trading volume of 2,943,165 shares, compared to its average volume of 2,277,598. Cellebrite DI Ltd. has a twelve month low of $9.58 and a twelve month high of $19.98. The stock has a market capitalization of $3.07 billion, a PE ratio of 55.87, a price-to-earnings-growth ratio of 1.73 and a beta of 1.18. The stock has a 50-day moving average price of $14.19 and a two-hundred day moving average price of $13.80.

Institutional Trading of Cellebrite DI

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Cellebrite DI by 16.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company's stock worth $3,362,000 after acquiring an additional 24,881 shares during the last quarter. Geode Capital Management LLC increased its position in Cellebrite DI by 16.2% during the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company's stock worth $5,029,000 after purchasing an additional 43,898 shares during the last quarter. Invesco Ltd. raised its stake in Cellebrite DI by 6.4% during the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company's stock worth $56,089,000 after purchasing an additional 209,473 shares during the period. First Trust Advisors LP purchased a new position in Cellebrite DI during the second quarter worth approximately $341,000. Finally, Marshall Wace LLP acquired a new position in shares of Cellebrite DI in the 2nd quarter valued at $4,472,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on CLBT. DA Davidson reduced their target price on shares of Cellebrite DI from $22.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, August 14th. Weiss Ratings lowered shares of Cellebrite DI from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, August 13th. Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a "buy" rating on the stock in a research note on Friday, August 14th. Lake Street Capital decreased their target price on shares of Cellebrite DI from $21.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, August 14th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating for the company in a research note on Friday, August 14th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $16.70.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source